2-hydrazino-5-methylbenzoic acid hydrochloride | 173034-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydrazino-5-methylbenzoic acid hydrochloride
• 英文别名: 2-Hydrazinyl-5-methylbenzoic acid
• CAS: 173034-19-0
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: VZYAAITZLIJNRH-UHFFFAOYSA-N

物化性质

• 沸点：
  340.3±30.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-hydrazino-5-methylbenzoic acid hydrochloride 在 盐酸 、 sodium hydride 作用下， 生成
  参考文献：
  名称：

  Pictet-Spengler reaction in trifluoroacetic acid. Large scale synthesis of pyridoindolobenzodiazepine as an atypical antipsychotic agent

  摘要：

  Traditional syntheses of benzodiazepines involve a Bischler-Napieralski reaction which is a three step process and gives low overall yields. An attractive alternative is to construct the diazepine ring under Pictet-Spengler conditions. This paper reports the synthesis of a novel pyridoindolo-benzodiazepine as a potent atypical antipsychotic agent. The key step in the synthesis is the ring formation of the diazepine ring in neat trifluoroacetic acid.

  DOI：

  10.1016/0040-4039(95)01812-v
• 作为产物：
  描述：

  5-methyl-2-(2-oxohydrazinyl)benzoic acid 在 溶剂黄146 、 锌 作用下， 生成 2-hydrazino-5-methylbenzoic acid hydrochloride
  参考文献：
  名称：

  Pictet-Spengler reaction in trifluoroacetic acid. Large scale synthesis of pyridoindolobenzodiazepine as an atypical antipsychotic agent

  摘要：

  Traditional syntheses of benzodiazepines involve a Bischler-Napieralski reaction which is a three step process and gives low overall yields. An attractive alternative is to construct the diazepine ring under Pictet-Spengler conditions. This paper reports the synthesis of a novel pyridoindolo-benzodiazepine as a potent atypical antipsychotic agent. The key step in the synthesis is the ring formation of the diazepine ring in neat trifluoroacetic acid.

  DOI：

  10.1016/0040-4039(95)01812-v

文献信息

• [EN] SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] PYRAZOLOQUINAZOLINONES ET PYRROLOQUINAZOLINONES SUBSTITUÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2016046404A1

  公开（公告）日：2016-03-31

  The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGlu Rs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明提供了通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物以及含有它们的药物组合物。此外，式(I)的化合物及其组合物被提供用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症，以及可以通过改变哺乳动物中的谷氨酸水平或信号传导而受影响的病症。这些通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物可以作为神经系统中对谷氨酸敏感的受体调节剂，特别是作为代谢型谷氨酸受体(mGluRs)的调节剂，这使得它们特别适合用于治疗和/或预防急性和慢性神经和/或精神疾病。
• [EN] NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS<br/>[FR] NOUVEAUX DERIVES D'INDOLE UTILES COMME INHIBITEURS DE FABP-4
  申请人：BIOVITRUM AB

  公开号：WO2004063156A1

  公开（公告）日：2004-07-29

  The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.

  本发明涉及新化合物（I），其中R0、R1、R2、R3、R4、R5、R6、R7、R8、A、B、n、X和Y如描述和权利要求中所定义；以及包含这些化合物的药物组合物，以及这些化合物在医学中的使用和用于制备作用于脂肪酸结合蛋白FABP-4的药物的方法。
• The Synthesis of Anthglutin and Its Analogues
  作者：Takeshi Kinoshita、Hiroko Watanabe、Sadamasa Minato

  DOI：10.1246/bcsj.54.2219

  日期：1981.7

  Anthglutin (1-γ-l-glutamyl-2-(2-carboxyphenyl)hydrazine) and its analogues were synthesized. Their inhibitory activity on γ-glutamyl transpeptidase was measured. 2-Carboxyphenyl derivatives, including anthglutin, showed inhibitory activity, while the other derivatives did not. The 2-carboxyl group seems to be essential for the inhibitory activity.

  合成了Anthglutin（1-γ-l-谷氨酰-2-(2-羧基苯基)肼）及其类似物，并测量了它们对γ-谷氨酰转肽酶的抑制活性。包括Anthglutin在内的2-羧基苯基衍生物表现出抑制活性，而其他衍生物则没有。2-羧基似乎对抑制活性是必不可少的。
• [EN] INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE<br/>[FR] INHIBITEURS DE LA LIPOAMIDE DÉSHYDROGÉNASE DE MYCOBACTERIUM TUBERCULOSIS
  申请人：UNIV CORNELL

  公开号：WO2022150574A1

  公开（公告）日：2022-07-14

  Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.

  本发明涉及用于抑制脂肪酰胺脱氢酶（Lpd）的化合物和治疗结核病的方法。
• Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
  申请人：Domain Therapeutics

  公开号：EP3000814A1

  公开（公告）日：2016-03-30

  The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明提供通式（I）的吡唑喹唑啉酮和吡咯喹唑啉酮衍生物以及含有它们的药物组合物。此外，本发明提供的式(I)化合物和含有它们的组合物可用于治疗和/或预防与谷氨酸能信号传导和/或功能改变有关的疾病，和/或可受哺乳动物体内谷氨酸水平或信号传导改变影响的疾病。这些通式（I）的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物可作为对谷氨酸敏感的神经系统受体的调节剂，特别是作为代谢型谷氨酸受体（mGluRs）的调节剂，这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神疾病。